Rona Therapeutics raises $35 million Series A+ financing

Shanghai, China-based Rona Therapeutics on Friday announced the completion of $35 million Series A+ financing.

This round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures.

LongRiver Investments, which will join the board of Rona in connection with the Series A+ financing, commented: “Rona Therapeutics has successfully brought two best-in-class siRNA metabolic programs into global development and demonstrated differentiated clinical data and platform value. We are impressed by the progress Rona has made in developing innovative siRNA pipeline and expanding into extrahepatic delivery in CNS and beyond. We look forward to partnering with Rona team to unlock potential of RNA medicine as transformative therapies to patients globally.”